Zobrazeno 1 - 10
of 41
pro vyhledávání: '"Philip J. Stella"'
Autor:
Saima N. Waqar, David R. Gandara, Vassiliki A. Papadimitrakopoulou, Karen Kelly, Gauri J. Kiefer, Hossein Borghaei, Mary W. Redman, Katherine Minichiello, Roy S. Herbst, Francisco Robert, Philip J. Stella
Publikováno v:
Clin Lung Cancer
Introduction The objective of the Lung-MAP sub-study S1400A was to evaluate the response rate to durvalumab, an anti-programmed death-ligand 1 (PD-L1) antibody, in patients with squamous non–small-cell lung cancer (SqNSCLC). Patients and Methods Pa
Autor:
Katherine M. Moxley, Samuel A. Jacobs, J. Li, Greg Yothers, Thomas J. George, J. Dorth, William A. Hall, R.A. Peterson, G. dePrisco, Marc J. Gollub, Bryan A. Faller, H.M. Gross, Y. N. You, Philip J. Stella, Theodore S. Hong, Mark A. Rosen, Michael G. Haddock, J.R. Grajo
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 111:S37
Purpose/Objective(s) Total neoadjuvant therapy (TNT) including chemotherapy (chemo) and concurrent chemo and radiotherapy (RT) is a promising strategy for rectal cancer. Characterizing tumor regression during TNT represents an important area of resea
Autor:
Peter C. Lucas, Marc J. Gollub, Tracey E. Schefter, Bryan A. Faller, Richard K. Valicenti, Mark A O'Rourke, William Parker, Greg Yothers, Philip J. Stella, Samuel A. Jacobs, Osama E. Rahma, Radhika Kainthla, Thomas J. George, Y. Nancy You, Lisa A. Kachnic, Elin R. Sigurdson, Katherine M. Moxley, Norman Wolmark, Theodore S. Hong, William A. Hall, Namrata Vijayvergia, Linda H. Colangelo, Marcia M. Russell
Publikováno v:
JAMA Oncol
Importance Total neoadjuvant therapy (TNT) is often used to downstage locally advanced rectal cancer (LARC) and decrease locoregional relapse; however, more than one-third of patients develop recurrent metastatic disease. As such, novel combinations
Autor:
Rachel Rabinovitch, Mothaffar F. Rimawi, Charles E. Geyer, Norman Wolmark, CK Osborne, SH Dyar, Luis Baez-Diaz, Eleftherios P. Mamounas, Patrick J. Flynn, Soonmyung Paik, Z Dayao, P Rastogi, Louis Fehrenbacher, Sandra M. Swain, Philip J. Stella, Reena S. Cecchini
Publikováno v:
Cancer Research. 77:S3-06
Background: Preclinical evidence has shown that in xenograft models with estrogen receptor (ER)+/HER2+ breast cancer, signaling through the ER pathway can be enhanced in the presence of anti-HER2 treatment and lead to treatment resistance. Concurrent
Autor:
Manmeet Ahluwalia, Helen A. Shih, Amyn M. Rojiani, Shawn Malone, Minesh P. Mehta, Lynn S. Ashby, John B. Fiveash, Maria Werner-Wasik, Minhee Won, Hsiang Hsuan Michael Yu, Philip J. Stella, Volker W. Stieber, Merideth M Wendland, Patrick Y. Wen, Nimish Mohile, Prakash Chinnaiyan, Andrew Y. Kee
Publikováno v:
Neuro-oncology. 20(5)
Background This phase II study was designed to determine the efficacy of the mammalian target of rapamycin (mTOR) inhibitor everolimus administered daily with conventional radiation therapy and chemotherapy in patients with newly diagnosed glioblasto
Autor:
Hanna Bandos, Norman Wolmark, Alexander H.G. Paterson, John T. Hamm, Patricia A. Ganz, Luis Baez-Diaz, John W Wilson, Edith A. Perez, Louis Fehrenbacher, Richard G. Margolese, Louise Provencher, Adam Brufsky, Patrick J Ward, Robert L Carolla, Philip J. Stella, Henry R Shibata, Aroop Mangalik, André Robidoux, Johnathan Polikoff
Publikováno v:
Cancer Research. 75:P3-12
Background NSABP B-36 compares 6 cycles of FEC-100 with 4 cycles of standard AC in pts with node-negative breast cancer. As reported separately, no significant differences between the two treatment arms were observed in the primary endpoint of diseas
Autor:
Randolph S. Marks, Philip J. Stella, Andrew V. Grainger, John Wright, Preston D. Steen, Garth D. Nelson, Thanyanan Reungwetwattana, Alex A. Adjei, Nathan R. Foster, Julian R. Molina
Publikováno v:
Lung Cancer. 85:245-250
Introduction To assess the efficacy and the Src-kinase inhibitor saracatinib (AZD-0530) after four cycles of platinum-based chemotherapy for extensive stage small cell lung cancer (SCLC). Methods Patients with at least stable disease received saracat
Autor:
Charles C. Williams, Kemp H. Kernstine, Philip J. Stella, David R. Gandara, James C. Moon, Ralph Zinner, Mary W. Redman, Royce F. Calhoun, Zhong Zheng, Philip C. Mack, Gerold Bepler, Vasco Oliveira
Publikováno v:
Cancer
BACKGROUND This cooperative group adjuvant phase 2 trial in patients with completely resected stage I non-small cell lung cancer with tumor diameters measuring ≥ 2 cm was designed to assess the feasibility and preliminary efficacy of assigning pati
Autor:
S. P. Kahanic, Paul J. Novotny, Robert J. Dalton, David P. Steensma, Philip J. Stella, Diane Prager, Shaker R. Dakhil, Jeff A. Sloan, Charles L. Loprinzi, Kendrith M. Rowland
Publikováno v:
Journal of Clinical Oncology. 29:97-105
Purpose Functional iron deficiency may impair response to erythropoiesis-stimulating agents (ESAs) in iron-replete patients with chemotherapy-associated anemia (CAA). This study evaluated whether coadministration of parenteral iron improves ESA effic
Autor:
Robert Deeter, David R. Spigel, Carroll Scroggin, Philip J. Stella, Edith P. Mitchell, Rafael G. Amado, Christopher Hagenstad, Seta Shahin, Tarek Chidiac, David McCollum, Allen Lee Cohn, J. Randolph Hecht, John Marshall
Publikováno v:
Journal of Clinical Oncology. 27:672-680
Purpose Panitumumab, a fully human antibody targeting the epidermal growth factor receptor, is active in patients with metastatic colorectal cancer (mCRC). This trial evaluated panitumumab added to bevacizumab and chemotherapy (oxaliplatin- and irino